Prostate artery embolization (PAE) is an image-guided, catheter-based treatment for urinary symptoms and obstruction associated with benign prostatic hyperplasia and prostate enlargement. Instead of entering the prostate through the urethra to cut or vaporize tissue, an interventional radiologist selectively blocks small arteries supplying the prostate. Reduced blood flow causes treated prostate tissue to undergo ischemic change and gradually shrink.
01. Prostate Artery Embolization: Indications, Technique and Treatment Role
What problem is Prostate Artery Embolization intended to treat?
PAE is intended to reduce lower urinary tract symptoms when benign prostate enlargement contributes meaningfully to bladder-outlet obstruction.
The anatomical relationship begins with the prostate gland, which lies below the bladder and surrounds the first portion of the urinary channel.
That portion is the prostatic urethra. When benign prostate tissue enlarges inward, the urethral lumen may become compressed and urinary resistance may rise.
This can contribute to:
- a weak urinary stream;
- difficulty starting urination;
- intermittent flow;
- straining;
- incomplete bladder emptying;
- increased post-void residual urine;
- and urinary retention in some men.
PAE approaches this problem differently from TURP, HoLEP, Aquablation or GreenLight PVP. Instead of directly removing obstructing tissue from inside the prostate, it targets the tissue’s arterial blood supply.
What happens before and during Prostate Artery Embolization?
Before PAE, a urological assessment is needed to determine whether benign prostate enlargement is sufficiently responsible for the urinary problem.
The wider evaluation may include symptom assessment, urinalysis, PSA when clinically appropriate, urinary-flow testing, post-void residual measurement and evaluation of prostate volume.
This matters because prostate enlargement does not automatically establish obstruction. FBU explains the relationship in prostate size, obstruction and BPH symptoms.
PAE is then performed by an interventional radiologist. Arterial access is commonly obtained through the femoral artery in the groin or the radial artery near the wrist.
A thin catheter is navigated through the arterial system toward the pelvic arteries, and digital subtraction angiography is used to identify the vessels supplying the prostate.
A smaller microcatheter is advanced selectively into the appropriate prostatic artery before embolic material is delivered.
For the wider BPH procedure pathway, see BPH Surgery and Minimally Invasive Procedures.
02. How Is Prostate Artery Embolization Performed?
Which anatomy, prostate size or disease factors affect Prostate Artery Embolization?
PAE is technically different from the transurethral procedures used elsewhere in BPH treatment because the interventional radiologist must navigate small and highly variable pelvic arteries.
The prostatic arterial supply can differ substantially between patients. Branches supplying the prostate can also communicate with arteries serving nearby structures such as the bladder, rectum and penis.
Careful angiographic mapping is therefore central to the procedure.
Modern PAE may use detailed angiography and, in some centers, cone-beam CT to better define arterial anatomy and reduce the risk of non-target embolization.
How does blocking prostate arteries make the gland smaller?
The embolic particles reduce blood flow through the treated prostatic arterial branches.
Reduced perfusion deprives selected prostate tissue of oxygen and nutrients. This produces ischemic injury and tissue necrosis, followed by remodeling and gradual reduction in prostate volume.
As the treated gland decreases in volume, compression around the prostatic urethra may decrease.
What are the main expected outcomes after Prostate Artery Embolization?
PAE can substantially improve urinary symptom scores and quality of life in appropriately selected men.
A randomized sham-controlled trial demonstrated that symptom improvement after PAE was substantially greater than after the sham procedure.
However, comparison with TURP shows an important limitation.
Current EAU evidence concludes that PAE is generally less effective than TURP at improving objective urinary parameters, including maximum urinary flow and post-void residual urine.
Five-year randomized evidence also found smaller improvements after PAE than after TURP. Mean maximum urinary flow increased by about 3.6 mL/s after PAE compared with about 9.3 mL/s after TURP in that study.
This means PAE can be clinically useful without being physiologically equivalent to a stronger tissue-removing operation.
03. Prostate Artery Embolization: Outcomes, Recovery and Procedure-Specific Trade-Offs
What does recovery after Prostate Artery Embolization usually involve?
PAE can often be performed as a day procedure under local anesthesia, sometimes with additional sedation.
Because there is no surgical incision into the prostate and no transurethral resection cavity, blood loss, catheterization time and hospital stay can be lower than with TURP.
Patients still need recovery monitoring after the embolized prostate begins its inflammatory and ischemic response.
Temporary symptoms may include:
- burning during urination;
- pelvic or perineal discomfort;
- increased urinary frequency or urgency;
- temporary blood in the urine;
- fatigue or feeling unwell;
- low-grade inflammatory symptoms;
- and temporary urinary retention in some patients.
A group of inflammatory symptoms occurring after embolization is commonly referred to as postembolization syndrome.
Why can urinary retention occur after PAE?
The prostate does not immediately shrink when its arterial supply is embolized.
Early inflammation and swelling can temporarily increase resistance around the urethra before later tissue shrinkage occurs.
This helps explain why acute urinary retention can occur despite the procedure ultimately being intended to improve bladder emptying.
Which urinary or sexual effects should be discussed before Prostate Artery Embolization?
Sexual outcomes after PAE are an area where claims should remain careful.
Some studies and meta-analyses report less sexual dysfunction after PAE than after TURP, and erectile function is often preserved.
However, current EAU evidence also emphasizes uncertainty when comparing erectile and ejaculatory outcomes directly between PAE and TURP.
PAE should therefore not be described as guaranteeing preservation of erection or ejaculation.
Urinary complications can include temporary retention, urinary tract infection, dysuria and persistent or recurrent symptoms.
What is non-target embolization?
One procedure-specific risk is accidental movement of embolic material into arteries supplying tissue outside the intended prostate target.
This is called non-target embolization.
Because pelvic arteries can have connections with vessels serving the bladder, rectum, seminal structures or penis, accurate mapping and selective microcatheter positioning are essential.
Serious ischemic injury to non-target organs is uncommon but can be clinically significant.
Modern imaging, operator training and careful embolization technique are intended to reduce this risk.
Does PAE involve radiation or contrast material?
Yes. PAE relies on fluoroscopy and angiographic imaging, so it exposes the patient to ionizing radiation.
Iodinated contrast material is also commonly used to visualize the arterial anatomy.
Radiation exposure should therefore form part of pre-procedure counseling, and kidney function, contrast reactions and other relevant medical factors may require additional planning.
04. Who Is Most Likely to Be Considered for Prostate Artery Embolization?
How does Prostate Artery Embolization compare with the closest alternative?
The strongest established comparison is between PAE and TURP. Both can improve BPH-related urinary symptoms, but the balance between invasiveness and degree of decompression differs.
The preceding procedure in the FBU pathway, GreenLight PVP, also reduces benign prostate obstruction but does so by vaporizing tissue through the urethra rather than reducing arterial blood flow.
| Feature | PAE | TURP |
|---|---|---|
| Approach | Catheter-based arterial embolization through radial or femoral access. | Endoscopic operation performed through the urethra. |
| Mechanism | Reduces prostate blood supply, producing gradual tissue shrinkage. | Directly resects obstructing prostate tissue. |
| Anesthesia | Can often be performed under local anesthesia. | Usually requires regional or general anesthesia. |
| Symptom improvement | Clinically meaningful in appropriately selected men. | Generally stronger long-term improvement. |
| Maximum urinary flow | Improves, but generally less than after TURP. | Greater average objective improvement. |
| Residual urine | Can decrease. | Generally greater reduction. |
| Blood loss | Usually lower. | Greater operative tissue disruption. |
| Hospital stay | Often shorter; day treatment may be possible. | Usually requires a more conventional postoperative pathway. |
| Retreatment | Higher probability of additional BPH treatment over time. | Generally more durable outlet decompression. |
| Tissue for pathology | No prostate tissue is removed for histopathology. | Resected tissue can be submitted for pathology. |
| Radiation | Uses fluoroscopic radiation. | Does not ordinarily require fluoroscopic radiation. |
Does prostate size affect PAE selection?
PAE does not have the same narrow prostate-volume range associated with some transurethral procedures.
Evidence reviewed by the EAU suggests that men with larger prostates may have a greater probability of a favorable response to PAE, although larger trials are still needed to define which prostate-volume groups benefit most.
This makes prostate-volume measurement clinically relevant, but prostate size should never be interpreted in isolation.
A large gland does not necessarily produce severe obstruction, and a smaller gland can sometimes cause significant outlet resistance depending on its shape and relationship to the bladder neck.
When is Prostate Artery Embolization unsuitable or followed by additional evaluation?
PAE may be a poor fit when the patient needs the strongest possible outlet decompression, when arterial anatomy prevents safe selective catheterization, when another operation is better matched to the anatomy or when symptoms are primarily caused by a problem other than prostate obstruction.
Pelvic vascular disease, marked arterial tortuosity or calcification can make selective access technically more difficult.
Kidney function and previous reactions to iodinated contrast may also affect procedural planning because angiography requires contrast material.
Importantly, PAE does not provide prostate tissue for pathological examination.
When PSA, prostate examination, imaging or other findings raise concern for prostate cancer or another diagnosis, that evaluation should be completed appropriately rather than assuming the urinary problem is uncomplicated BPH.
FBU’s broader diagnostic pathway is explained in How BPH Is Diagnosed.
Why is PAE not simply a replacement for prostate surgery?
The available evidence does not support treating all procedures as interchangeable.
In a five-year randomized comparison, PAE improved urinary symptoms but was inferior to TURP for several long-term patient-reported and objective outcomes.
The same study showed substantially greater improvement in maximum urinary flow and reduction of residual urine after TURP.
Current EAU guidance therefore recommends discussing PAE with men who value a minimally invasive approach and understand that urinary outcomes may be less optimal and retreatment may be more likely than after TURP.
Summary
- Prostate artery embolization is a catheter-based treatment for BPH-related urinary symptoms and obstruction.
- It is performed through an artery rather than through the prostatic urethra.
- A microcatheter is selectively advanced into the arteries supplying the prostate.
- Embolic particles reduce arterial blood flow, producing ischemic injury and gradual prostate shrinkage.
- Symptom improvement develops over time rather than from immediate removal of prostate tissue.
- PAE can improve urinary symptom scores, quality of life, urinary flow and residual urine.
- TURP generally produces stronger improvements in maximum urinary flow and post-void residual urine.
- PAE generally favors blood loss, catheterization time and hospital stay compared with TURP.
- Later retreatment is more common after PAE than after TURP.
- PAE can often be performed under local anesthesia using femoral or radial arterial access.
- Pelvic arterial anatomy must be carefully mapped to reduce the risk of non-target embolization.
- PAE involves fluoroscopic radiation and iodinated contrast exposure.
- Sexual function is often preserved, but current evidence does not justify guaranteeing erectile or ejaculatory preservation.
- No tissue specimen is obtained, so appropriate evaluation of concerning prostate findings remains important before treatment.
- Current guidance emphasizes joint patient selection and follow-up by urology and appropriately trained interventional radiology teams.
Educational disclaimer: This article provides general medical education and does not recommend prostate artery embolization or another BPH procedure for an individual. Treatment selection requires evaluation of urinary symptoms, prostate anatomy, prostate volume, bladder function, vascular anatomy, medical risk and patient priorities by appropriately qualified clinicians.
Explore the Prostate and BPH Pathway
To understand why prostate enlargement can affect urination, start with Prostate Health, Prostate Anatomy and Function, and the Prostatic Urethra.
For prostate-size assessment, see How Prostate Volume Is Measured.
For the disease pathway, continue through BPH and Enlarged Prostate and How BPH Is Diagnosed.
For procedural treatment options, see BPH Surgery and Minimally Invasive Procedures.
The preceding procedure in this treatment sequence is GreenLight Laser PVP for BPH.
Evidence Sources
- European Association of Urology. Management of Non-neurogenic Male LUTS — Prostatic Artery Embolisation. Current guideline evidence covering technique, comparative effectiveness, safety, retreatment, radiation exposure and multidisciplinary selection.
- Society of Interventional Radiology. 2026 Practice Guidance Document for Prostatic Artery Embolization. Updated guidance on patient selection, procedural technique, periprocedural care, outcome assessment and safety.
- Müllhaupt G, et al. Prostatic Artery Embolisation Versus Transurethral Resection of the Prostate for Benign Prostatic Obstruction: 5-Year Outcomes of a Randomised Trial. European Urology Focus. PMID: 38531756.
- Svarc P, et al. Postembolization Syndrome after Prostatic Artery Embolization: A Systematic Review. Diagnostics. PMID: 32878325.
